Advances in the Management of Prostate Cancer (Module 1)
This activity has been designed to meet the educational needs of community urologists, oncologists, and other healthcare providers involved in the diagnosis, treatment, or management of patients with prostate cancer.
Over the past 13 years, several new agents have been approved to treat patients with metastatic prostate cancer (PC). As a result, clinical guidelines have been updated frequently that support the expanding the role of combination therapy, particularly by introducing chemotherapy earlier to patients with castration-sensitive progressive disease. There is also growing demand for providers who are capable of implementing multimodal treatments. This interactive activity will discuss advances in the management of patients with metastatic PC, specifically metastatic castration (hormone)-sensitive PC, immunotherapy, chemotherapy, second-generation therapies, considerations for sequencing therapies, and emerging therapies.
The goal of this program is to provide urologists and oncologists with the most up-to-date information on treatment options and strategies for metastatic castration-resistant PC.
Upon completion of this activity, participants will be better able to do the following:
- EVALUATE emerging therapies for castration-sensitive prostate cancer.
- IMPLEMENT appropriate therapy combinations and sequencing for patients with advanced metastatic prostate cancer.
- APPLY all available therapy modalities to propose individualized office-based treatment plans for advanced prostate cancer patients.
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Raoul S. Concepcion, MD, FACS (Chair)||
Consultant/Advisor: Astellas Pharma US Inc, Bayer AG, Cellay Inc, Dendreon Inc, Genomic Health, and Pfizer Inc.
Speaker's Bureau: Amgen Inc, Astellas Pharma US Inc, Bayer AG, Dendreon Inc, Pfizer Inc.
|Evan Y. Yu, MD||
Consultant/Advisor and Research Grant: Bayer AG, Genentech Inc, Merck & Co Inc.
Consultant/Advisor: AstraZeneca, Bayer AG, EMD Serono, Janssen Pharmaceuticals, Inc, and Medivation Inc.
Research Grant: Agensys Inc, Dendreon Inc, and Eli Lilly and Company
Lou Settembrino; Mary Gabb, MS; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Sanofi Genzyme.
Jointly provided by the Elsevier Office of Continuing Medical Education and ASiM CE, LLC.
CME CREDIT (PHYSICIANS)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and ASiM CE, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, ASiM CE, LLC and Sanofi Genzyme do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
Release date: February 15, 2018
Expiration date: February 14, 2019